Sight Sciences (SGHT) Q2 2025: OmniEdge Drives 6% Account Growth Amid LCD Headwinds
OmniEdge adoption and targeted commercial execution propelled Sight Sciences to record ordering accounts in Q2, despite ongoing LCD reimbursement restrictions in surgical glaucoma. Management’s guidance raise signals confidence in execution, even as dry eye remains a long-term catalyst awaiting payer coverage. Investors should watch for margin pressure from tariffs and the timing of TierCare reimbursement as critical levers for the second half of 2025.
Summary
- OmniEdge Launch Expands Ordering Accounts: New product introduction and reactivation strategies lifted account growth and utilization.
- LCD Restrictions Contain Glaucoma Volume: Medicare policy headwinds continue to weigh on procedural mix and utilization rates.
- TierCare Reimbursement Remains the Swing Factor: Payer decision timing is pivotal for unlocking dry eye’s growth potential.
Performance Analysis
Sight Sciences delivered resilient top-line results in Q2 2025, with total revenue of $19.6 million, down 8% year-over-year, as the surgical glaucoma segment outperformed internal expectations despite ongoing policy headwinds. The surgical glaucoma business, which accounted for nearly all revenue, declined 5% compared to the prior year but grew 12% sequentially, reflecting a strong rebound from Q1 and robust execution in account expansion and product adoption. Ordering accounts reached a new record, up 6% sequentially and 4% year-over-year, as the company’s re-engagement and new account initiatives gained traction.
Gross margin remained strong at 85%, though down slightly from the prior year due to tariff costs and product mix shifts. Dry eye revenue, at $0.3 million, continued to contract as Sight Sciences prioritized reimbursement groundwork for TierCare, temporarily sacrificing near-term sales in pursuit of long-term market access. Operating expenses declined 9% year-over-year, driven by lower legal fees, with adjusted operating expenses down 8%. Net loss narrowed modestly, and cash burn improved, ending the quarter with $101.5 million in cash and $40 million in debt.
- OmniEdge Uptake: Surgeons responded positively to the new OmniEdge platform, driving incremental account and utilization growth.
- Tariff Exposure Managed: Estimated full-year tariff impact on COGS reduced to $1-1.5 million, but future rates remain uncertain.
- Dry Eye Strategy: Revenue intentionally constrained as the company focuses on building the payer evidence base for TierCare reimbursement.
While LCD reimbursement changes continue to depress total procedure volumes, Sight Sciences is gaining share in a contracting market, aided by commercial discipline and product innovation. The company’s dry eye segment remains a latent growth lever, with operational infrastructure in place to scale rapidly upon reimbursement wins.
Executive Commentary
"We reached a record high for ordering accounts in the second quarter, up 6% sequentially and 4% versus the same period in the prior year, due to both re-engagement efforts with accounts who had ordered previously but had gone dormant, and also new accounts ordering for the first time."
Paul Bedawi, Co-founder and Chief Executive Officer
"We are raising our full year 2025 revenue guidance to $72 to $76 million, while maintaining our full year 2025 guidance on adjusted operating expenses."
Allie Bauerlein, Chief Financial Officer
Strategic Positioning
1. Surgical Glaucoma: Defending and Expanding Share
Sight Sciences is leveraging its market-leading position in implant-free MIGS (minimally invasive glaucoma surgery) to gain share, even as the overall procedural market contracts due to LCD (local coverage determination) restrictions. The company’s commercial team is focusing on both reactivating dormant accounts and onboarding new ones, while the OmniEdge launch offers surgeons greater procedural customization, supporting incremental utilization and differentiation in a competitive field.
2. Dry Eye: Building the Foundation for Reimbursed Growth
The dry eye business (TierCare) is in deliberate holding mode, with minimal near-term revenue as Sight Sciences pursues payer coverage. The company has completed pivotal clinical and health economic studies, including the 24-month Sahara RCT and a cost utility analysis, and is now engaged in advanced discussions with commercial and MAC (Medicare Administrative Contractor) payers. Management’s conviction in eventual reimbursement is high, but the timeline remains outside their control.
3. Operational Discipline: Margin Management and Cost Control
Sight Sciences maintained high gross margins and reduced operating expenses, even as tariffs and product mix pressured COGS. The company’s manufacturing strategy includes expanding to third-party sites, with OmniEdge production expected to begin at new facilities in Q1 2026, which should help diversify supply risk and potentially mitigate tariff exposure.
4. Innovation Pipeline: Iterative Product Development
Continuous evolution of the Omni platform (OmniEdge, OmniErgo) is central to retaining surgeon loyalty and adapting to changing procedural workflows. The company’s feedback loop with customers and rapid iteration support its competitive moat and ability to respond to emerging clinical needs.
5. Legal and Regulatory Dynamics: Patent Litigation and Tariffs
The outcome of the Alcon patent litigation and ongoing USPTO reexamination proceedings may impact potential royalty revenue and legal cost exposure. Additionally, tariff policy remains a fluid risk, with the current pause on China tariffs set to expire in August, introducing cost unpredictability for the surgical glaucoma segment.
Key Considerations
Sight Sciences’ Q2 results reflect a company executing well against structural market headwinds, while positioning for future upside tied to reimbursement and product innovation.
Key Considerations:
- Account Growth Outpaces Utilization: Record ordering accounts signal successful commercial initiatives, even as per-account volumes remain pressured by LCD policy.
- OmniEdge as a Differentiator: The launch of OmniEdge is driving incremental interest and procedural adoption, supporting share gains in a static market.
- Dry Eye Remains a Binary Upside: Near-term revenue is muted, but infrastructure and published data position TierCare for rapid scaling if payer coverage materializes.
- Margin Resilience Faces Tariff Risk: Gross margin remains high, but future tariff changes could erode profitability unless mitigated by supply chain adjustments.
- Guidance Reflects Cautious Optimism: Management’s raised revenue outlook is tempered by conservatism around market dynamics and reimbursement timing.
Risks
Reimbursement uncertainty for TierCare remains the single largest risk, with timing and payment levels outside management’s control. Regulatory volatility, including LCD policy changes and tariff rate resets, could create further headwinds for both revenue and margin. Patent litigation outcomes and potential invalidation of key claims in the Alcon dispute may impact future royalty streams and legal costs. Competitive intensity in MIGS is persistent, with new entrants and evolving surgeon preferences posing ongoing share risk.
Forward Outlook
For Q3 2025, Sight Sciences guided to:
- Mid-single digit year-over-year decline in surgical glaucoma revenue, reflecting tough comps and continued LCD pressure.
- Continued minimal dry eye revenue until reimbursed market access is achieved.
For full-year 2025, management raised revenue guidance to $72 to $76 million, maintaining adjusted operating expense guidance at $101 to $105 million. Management highlighted:
- Tariff exposure for surgical glaucoma COGS now expected at $1-1.5 million, down from prior estimates.
- OmniEdge manufacturing expansion to third-party sites begins Q1 2026, supporting supply chain flexibility.
Takeaways
Sight Sciences is executing commercial and operational levers to defend share and preserve margin in a difficult reimbursement climate, while positioning for outsized upside from TierCare reimbursement and ongoing product innovation.
- Commercial Execution: Record account growth and OmniEdge adoption demonstrate strong sales discipline and product-market fit, even as per-account utilization lags.
- Strategic Patience: The company is sacrificing near-term dry eye revenue to build the payer evidence base, betting on a meaningful inflection if coverage is secured.
- Watch Reimbursement and Tariff Policy: The timing and magnitude of TierCare coverage, and any tariff reset, will dictate the pace and scale of margin and revenue expansion in 2026.
Conclusion
Sight Sciences’ Q2 results highlight a business navigating reimbursement headwinds through commercial agility and product innovation, while keeping its sights set on transformative dry eye market access. Investors should monitor the interplay of surgical glaucoma share, tariff exposure, and the binary outcome of TierCare reimbursement for the next leg of the story.
Industry Read-Through
The experience of Sight Sciences underscores the importance of payer policy in medtech adoption cycles, particularly in procedure-driven markets like ophthalmology. Companies relying on new procedural codes or shifting reimbursement frameworks must build robust clinical and economic evidence to unlock growth, often at the expense of near-term revenue. The rapid iteration of product platforms (like OmniEdge) and commercial focus on account activation are critical for defending share in contracting or static markets. Tariff and supply chain risks remain a sector-wide concern, especially for device companies with exposure to China. Investors in the ophthalmology and broader medtech space should expect similar dynamics as LCD changes and payer scrutiny reshape procedural volumes and margin structures.